All In Biotech

Drug Trial Radar · NCT02954991

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

161

Actual

Start

Nov 7, 2016

Primary completion

Nov 4, 2021

Study completion Nov 4, 2021

Sponsor

Lead sponsor
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 4, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • GlesatinibDrug

    Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor

  • SitravatinibDrug

    Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

  • MocetinostatDrug

    Mocetinostat is an HDAC inhibitor.

  • NivolumabDrug

    nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.Time frame: Up to 40.6 months

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Yuma Regional Medical Center

    Yuma, Arizona

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • City of Hope National Medical Center

    Duarte, California

  • University of California San Diego

    La Jolla, California

  • University of California San Francisco Comprehensive Cancer Center

    San Francisco, California

  • University of California Los Angeles - Torrance - Community Cancer Care

    Santa Clarita, California

  • Rocky Mountain Cancer Centers - Denver - Midtown

    Denver, Colorado

  • Baptist Health

    Louisville, Kentucky

  • Henry Ford Hospital

    Detroit, Michigan

  • Minnesota Oncology Hematology, P.A.

    Minneapolis, Minnesota

  • University of Minnesota Masonic Cancer Center

    Minneapolis, Minnesota

  • Saint Francis Cancer Treatment Center

    Grand Island, Nebraska

  • Oncology Hematology Care-Blue Ash

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Hematology Oncology Associates - Barnett Office

    Medford, Oregon

  • Northwest Cancer Specialists, P.C.

    Tualatin, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Vanderbilt University

    Nashville, Tennessee

  • Texas Oncology - South Austin

    Austin, Texas

  • USOR - Texas Oncology - Denison Cancer Center

    Denison, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology - Tyler

    Tyler, Texas

  • Virginia Cancer Specialist

    Fairfax, Virginia

  • University of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.